Abstract #449
Key Points:
- HER2 is amplified in many solid tumors but also expressed in healthy tissue, increasing on-tumor, off-target toxicity (OTOTT) risk
- TMR CARs exploit tumor metabolism to improve selectivity and reduce OTOTT
- Single-center, investigator-initiated, dose-escalation trial enrolled 12 patients with HER2-positive Stage IV solid tumors (3 gastric, 1 esophageal, 4 colorectal, 4 breast).
- No dose-limiting toxicities (DLTs), severe adverse events (SAEs), or on-target off-tumor toxicities (OTOTT) at any dose level
- Deep and durable response observed in gastroesophageal cancer, including an ongoing 100% PR at 36 weeks in a gastric cancer patient
